Article: Generex Biotechnology Completes Acquisition of Antigen Express.

Generex Biotechnology Corporation announced today the completion of its acquisition of all of the issued and outstanding shares in the capital of Antigen Express, Inc. in exchange for approximately 2.9 million shares of Generex common stock. Dr. Joseph V. Gulfo, MD, MBA is the President, Chief Executive Officer and a director of Antigen Express. Dr. Gulfo is also expected to join the board of directors of Generex.

Antigen Express will operate as a wholly owned subsidiary of Generex focused on the development of immunomedicines for the treatment of malignant, infectious, autoimmune and allergic diseases. The company's potential products are based on two ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!